We are a spin-off from the Ludwig-Maximilians-University Munich. Our mission is to transform patient stratification in targeted cancer therapy with a focus on antibody-drug conjugate (ADC) therapies by providing innovative, functional biomarker solutions. Through our proprietary High-Affinity Probe Technology, we enable more precise patient selection, helping to optimize patient stratification, clinical trial designs and accelerate the development of targeted cancer therapies. Our goal is to improve the outcomes and quality of life for cancer patients of all ages and cancer types by delivering more accurate and actionable diagnostic insights.
Dr. Andreas Beck
Co-Founder & Chief Executive Officer
Dr. Alexander Beck
Co-Founder & Chief Scientific Officer
Dr. Dominikus Huber
Chief Medical Officer
We invite you to connect with us to explore how our High-Affinity Probe (HAP) technology can address your research and clinical objectives. Whether your focus is on custom probe development, enhancing clinical trial strategies, or advancing therapeutic profiling, our team is ready to provide tailored support and expert guidance.
Contact us to discuss your specific needs, request detailed information, or learn more about how HAP technology can contribute to your success in drug development and precision oncology.
